FDA Approves First Drug to Treat Rare Metabolic Disorder

Today, the FDA approved the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder which causes recurrent kidney stones and loss of kidney function.

Source: FDA Center for Drug Evaluation and Research - What's New - November 23, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news